SPRO · CIK 0001701108 · FY2025 live · 2025-12-31
Spero Therapeutics, Inc.
View as
Model
Classic Z
FY2025
−4.08
Zone
Distress
Prior
—
Market DD
—
1y PD
—
Meridian Rank
40
0–100 · Classic Z tape · not a PD
Book standing
19
Year change
—
Market PD
—
O-score
96
Events on this name
Same published rows as Today. Not a live recompute.
Market PD unavailable
watch · 41
−4.08
Z″ −8.90
Score −4.08 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.851.2 × = 1.02X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−6.541.4 × = −9.16X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
0.093.3 × = 0.30X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
5.960.6 × = 3.58X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.181 × = 0.18
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings rather than invent a series.
Overview
rule-v1
Spero Therapeutics, Inc. is on classic Z at −4.08 (distress) for FY2025, from an SEC 10-K. Retained earnings / assets is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers; buybacks can send retained earnings negative at otherwise healthy issuers, and X4 is book equity, not market cap.
Book screen Distress; market PD —. Tape not priced — not a single default call.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 34th percentile in Healthcare.
- GANXDistressGain Therapeutics, Inc.−4.08
- NMADDistressNOMAD POWER SOLUTIONS, INC.−4.07
- INSMDistressINSMED Inc−4.04
- OBIODistressOrchestra BioMed Holdings, Inc.−4.04
- ZBIODistressZenas BioPharma, Inc.−4.13
- BRNSDistressBarinthus Biotherapeutics plc.−4.02
- TNYADistressTenaya Therapeutics, Inc.−4.00
- LNSRDistressLENSAR, Inc.−3.98
KPI widgets
Current assets
$67M
Total assets
$69M
Current liabilities
$9M
Total liabilities
$10M
Working capital
$58M
Retained earnings
−$451M
EBIT
$6M
Total sales
$13M
Book equity
$59M
Accession 0001193125-26-126192. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as does not rewrite the live rank. X4 is book equity. Pulled 13 Sept 2026.